LAVA Therapeutics (LVTX)

• Market cap: $32.6M
• 1 day: -0.80%
• 5 days: -10.79%
• 1 month: -0.80%
• 3 months: 24.00%
• 6 months: -34.74%
• Year to date: 20.39%
• 1 year: -58.25%
• 5 years: -90.08%
• 10 years: -90.08%
• Sector: Healthcare
• Industry: Biotechnology

About: LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Employees: 34

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

10.9% more ownership

Funds ownership: 13.73% [Q3] → 24.62% (+10.9%) [Q4]

5% more funds holding

Funds holding: 21 [Q3] → 22 (+1) [Q4]

3% more capital invested

Capital invested by funds: $5.99M [Q3] → $6.15M (+$164K) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1.50 21% upside
• Avg. target: $1.50 21% upside
• High target: $1.50 21% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Arthur He 6% 1-year accuracy 2 / 32 met price target

21% upside $1.50

Neutral Reiterated

31 Mar 2025